Jasper Therapeutics
JSPR
40 hedge funds and large institutions have $63.7M invested in Jasper Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 13 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
0.28% more ownership
Funds ownership: 7.98% → 8.26% (+0.28%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 46 → 40 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
47% less capital invested
Capital invested by funds: $120M → $63.7M (-$56.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.72M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$1.69M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.13M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$765K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$641K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.64M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$685K |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$671K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$653K |
| 5 |
Legal & General Group
London,
United Kingdom
|
-$110K |
JSPR Hedge Fund Activity: Q3 2023 in Review
40 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2023, worth a combined $63.7M — down 47% from $120M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of JSPR and 7 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 11 added.
The largest buyer was Sphera Funds Management, adding an estimated $1.72M. The largest seller was Citadel Advisors, cutting an estimated $1.64M.
- 40 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2023, down from 46 in Q2 2023.
- Funds reported $63.7M of Jasper Therapeutics stock for Q3 2023, down 47% quarter-over-quarter.
- 7 funds opened new Jasper Therapeutics positions in Q3 2023 and 13 closed out, a net change of -6 holders.
- The largest Jasper Therapeutics buyer in Q3 2023 was Sphera Funds Management, an estimated $1.72M added.
- The largest Jasper Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $1.64M sold.
Based on aggregated 13F filings for Q3 2023.